Company / R&D per Share
Catalyst Pharmaceuticals Partners, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.10
FY2025
5-year range
$0.10 / $0.87
FY2021-FY2025
Trend
-0.9%
vs FY2024
Sector context
#201 of 208
Health Care
What the data says
Among 208 Health Care companies, Catalyst Pharmaceuticals Partners, Inc. is in the bottom 3% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $0.10 in FY2025 to $0.87 in FY2023.
Based on SEC 10-K filings.
0.10 in FY2025 with a 5-year CAGR of -8.3%.
Declined from $0.87 to $0.10 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -18.0%
- 5-Year CAGR
- -8.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 208This company $0.10 Sector average $28.77
▼
-99.6% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 0.9% year-over-year.
- Ranks #201 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.10 | -0.9% |
| FY2024 | $0.10 | -88.0% |
| FY2023 | $0.87 | +362.5% |
| FY2022 | $0.19 | +14.3% |
| FY2021 | $0.16 | +3.1% |
| FY2020 | $0.16 | -13.0% |
| FY2019 | $0.18 | -5.6% |
| FY2018 | $0.19 | +36.6% |
| FY2017 | $0.14 | +3.8% |
| FY2016 | $0.14 | -3.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026